 |
|
Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers
March 11, 2008Recurrent low-grade serous carcinoma, a rare type of ovarian cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovarian cancers, according to researchers from The University of Texas M. D. Anderson Cancer Center. The findings were reported at the Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancers.
The retrospective study is the first to analyze how women with low-grade tumors respond to chemotherapy in recurrent setting and confirms clinical impressions that the tumors are chemoresistant, said lead author David M. Gershenson, M.D., professor and chair of the Department of Gynecologic Oncology at M. D. Anderson. Previous studies have shown similar tumor resistance in newly diagnosed patients, and there is currently no standard of care for women facing the disease.
The results support a growing body of research that shows low-grade ovarian tumors behave differently than their high-grade counterparts, genetically and clinically. "In order to make meaningful advances in treatment, women with low-grade ovarian tumors must not be grouped together with those with more common ovarian tumors. They require unique consideration and more targeted treatment options for a better chance of survival," Gershenson said.
Gershenson and his colleagues identified all patients treated for recurrent low-grade serous carcinoma of the ovary seen at M. D. Anderson from 1990 through 2007 using databases from the Department of Gynecologic Oncology. Out of 52 patients with sufficient clinical information with which to assess response to one or more of 98 different chemotherapy regimens, the overall response rate was only 4 percent. Specifically, researchers found:
* Among 24 patients who received carboplatin for platinum-sensitive disease, there were two partial responses and one complete response.
* Of 11 patients who received a taxane/platinum combination for platinum-sensitive disease, no objective responses were observed.
* In the entire platinum-sensitive cohort, the overall response rate was only 6 percent.
* No response was observed in women with platinum-resistant disease to standard chemotherapy agents such as liposomal doxorubicin; topotecan; hexamethylmelamine; oral VP-16; xeloda and gemcitabine. One patient had a partial response to paclitaxel. The overall response rate in this subgroup was 2 percent.
* Sixty-one (62 percent) of the regimens stabilized the disease from 8 to 79 weeks, with a median of 22 weeks.
* In 18 instances of stable disease, CA125 levels decreased by 50 percent or more.
Gershenson said that these results compared unfavorably to findings from trials of more common ovarian cancers. "It is unclear whether the high rate of stable disease is more reflective of tumor biology of low-grade serous carcinoma of the ovary or of the therapy regimen administered. However, since these tumors do not respond to conventional types of chemotherapies, new agents to treat these tumors must be identified and tested," said Gershenson.
One area to explore further is hormonal therapy, a treatment that has been shown to have some activity against low-grade serous carcinoma, he said. A detailed analysis of the M.D. Anderson experience with hormonal therapy is planned in the near future.
Low-grade serous carcinoma represents about ten percent of all serous ovarian cancers. The disease is characterized by a young age at diagnosis - an average of 42 years old, versus more common ovarian cancers, which are generally diagnosed at about 60 years old. In addition, the median overall survival of women with low-grade serous carcinomas is much longer than that of patient with high-grade ovarian cancers-82+ months versus 50-67 months in various reported series.
Two-Tier Grading System Advances Better Treatment Options
Histologic grade has been shown to be one of the most important prognostic factors in ovarian serous carcinoma cases. However, no universal grading system exists. Over the last 15 years, researchers at M. D. Anderson have developed a two-tier grading system for serous carcinoma of the ovary (low and high), based on knowledge that this type of epithelial ovarian cancer comprises not one homogenous group of tumors but rather two distinct phenotypes.
Historically, a three-tier grading system to classify tumors has been used, but there has been no precise mechanism to define the thresholds between the grades, particularly grades two and three. Consequently, there were variations in designating how ovarian tumors should be classified and ultimately, treated.
Rare Ovarian Tumors Receive Increasing Attention
The study of rare cancers, such as low-grade serous carcinoma of the ovary, brings inherent challenges, including the limited number of cases to examine, difficulty in obtaining tissue samples, low funding, and the small pool of investigators working on research, according to Gershenson.
Recognizing the need for more research, the Gynecologic Oncology Group, a National Cancer Institute-funded cooperative group, recently established a rare tumor committee that has initiated a separate series of clinical trials for recurrent low-grade serous carcinoma as well as for other rare ovarian cancers.
Gershenson said that changing the design of clinical trials to segregate patients is key. "In addition to providing direct benefits to patients and their families, the study of rare tumors can also uncover information about the etiology, biology, and treatment of more common cancers."
University of Texas M. D. Anderson Cancer Center
Gershenson and his colleagues identified all patients treated for recurrent low-grade serous carcinoma of the ovary seen at M. D. Anderson from 1990 through 2007 using databases from the Department of Gynecologic Oncology. Out of 52 patients with sufficient clinical information with which to assess response to one or more of 98 different chemotherapy regimens, the overall response rate was only 4 percent. Specifically, researchers found:
* Among 24 patients who received carboplatin for platinum-sensitive disease, there were two partial responses and one complete response.
* Of 11 patients who received a taxane/platinum combination for platinum-sensitive disease, no objective responses were observed.
* In the entire platinum-sensitive cohort, the overall response rate was only 6 percent.
* No response was observed in women with platinum-resistant disease to standard chemotherapy agents such as liposomal doxorubicin; topotecan; hexamethylmelamine; oral VP-16; xeloda and gemcitabine. One patient had a partial response to paclitaxel. The overall response rate in this subgroup was 2 percent.
* Sixty-one (62 percent) of the regimens stabilized the disease from 8 to 79 weeks, with a median of 22 weeks.
* In 18 instances of stable disease, CA125 levels decreased by 50 percent or more.
Gershenson said that these results compared unfavorably to findings from trials of more common ovarian cancers. "It is unclear whether the high rate of stable disease is more reflective of tumor biology of low-grade serous carcinoma of the ovary or of the therapy regimen administered. However, since these tumors do not respond to conventional types of chemotherapies, new agents to treat these tumors must be identified and tested," said Gershenson.
One area to explore further is hormonal therapy, a treatment that has been shown to have some activity against low-grade serous carcinoma, he said. A detailed analysis of the M.D. Anderson experience with hormonal therapy is planned in the near future.
Low-grade serous carcinoma represents about ten percent of all serous ovarian cancers. The disease is characterized by a young age at diagnosis - an average of 42 years old, versus more common ovarian cancers, which are generally diagnosed at about 60 years old. In addition, the median overall survival of women with low-grade serous carcinomas is much longer than that of patient with high-grade ovarian cancers-82+ months versus 50-67 months in various reported series.
Two-Tier Grading System Advances Better Treatment Options
Histologic grade has been shown to be one of the most important prognostic factors in ovarian serous carcinoma cases. However, no universal grading system exists. Over the last 15 years, researchers at M. D. Anderson have developed a two-tier grading system for serous carcinoma of the ovary (low and high), based on knowledge that this type of epithelial ovarian cancer comprises not one homogenous group of tumors but rather two distinct phenotypes.
Historically, a three-tier grading system to classify tumors has been used, but there has been no precise mechanism to define the thresholds between the grades, particularly grades two and three. Consequently, there were variations in designating how ovarian tumors should be classified and ultimately, treated.
Rare Ovarian Tumors Receive Increasing Attention
The study of rare cancers, such as low-grade serous carcinoma of the ovary, brings inherent challenges, including the limited number of cases to examine, difficulty in obtaining tissue samples, low funding, and the small pool of investigators working on research, according to Gershenson.
Recognizing the need for more research, the Gynecologic Oncology Group, a National Cancer Institute-funded cooperative group, recently established a rare tumor committee that has initiated a separate series of clinical trials for recurrent low-grade serous carcinoma as well as for other rare ovarian cancers.
Gershenson said that changing the design of clinical trials to segregate patients is key. "In addition to providing direct benefits to patients and their families, the study of rare tumors can also uncover information about the etiology, biology, and treatment of more common cancers."
University of Texas M. D. Anderson Cancer Center
Carcinoma News and Current Carcinoma Events RSSEndocrine Society releases guideline on diagnosis and treatment of primary aldosteronism
The Endocrine Society has released a new clinical practice guideline for the detection, diagnosis, and treatment of patients with primary aldosteronism. The guidelines appear in the September issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society.
History of nonmelanoma skin cancer is associated with increased risk for subsequent malignancies
Individuals with a history of nonmelanoma skin cancer (NMSC) are at increased risk for other cancers, according to a study published in the August 26 online issue of the Journal of the National Cancer Institute.
Angiotensin inhibitors and receptor blockers linked to lower risk of nonmelanoma skin cancer
The use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) was associated with a reduced risk of basal cell or squamous cell skin cancers in U.S. veterans, researchers report in the August 26 online issue of the Journal of the National Cancer Institute.
To protect against liver disease, body puts cells 'under arrest'
A stable form of cell-cycle arrest known to offer potent protection against cancer also limits liver fibrosis, a condition characterized by an excess of fibrous tissue, according to a new report in the August 22nd Cell, a Cell Press publication.
Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage
Although post-reproductive life in humans is often associated with decline and a loss of powers, an analogous state in certain cells -- called senescence -- is proving to be one of ironic potency. Scientists at Cold Spring Harbor Laboratory (CSHL) today reported that a particular class of senescent liver cells orchestrates a sequence of events in living mice that can limit fibrosis, a natural response of the liver to acute damage.
Researchers discover scent of skin cancer
According to new research from the Monell Center, odors from skin can be used to identify basal cell carcinoma, the most common form of skin cancer. The findings, presented at the 236th meeting of the American Chemical Society, may open doors to development of new methods to detect basal cell carcinoma and other forms of skin cancer.
UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies
In the budding field of nanotechnology, scientists already know that size does matter. But now, researchers at the University of North Carolina at Chapel Hill have shown that shape matters even more - a finding that could lead to new and more effective methods for treating cancer and other diseases, from diabetes and multiple sclerosis to arthritis and obesity.
New Male Circumcision Device for HIV Prevention Studied by NewYork-Presbyterian/Weill Cornell
With the recent endorsement by the World Health Organization (WHO) and scientists worldwide of adult male circumcision as an important strategy for HIV prevention, there is increased urgency to develop safe and cost-effective circumcision services. This is especially the case in Africa where HIV/AIDS continues to spread at an epidemic rate.
Nanoparticles + light = dead tumor cells
Medical physicists at the University of Virginia have created a novel way to kill tumor cells using nanoparticles and light.
Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the efficacy of imiquimod, a clinically important immune response modifier with potent antiviral and antitumor activity, is dependent on the Opioid Growth Factor (OGF)-OGF receptor (OGFr) axis for its action.
More Carcinoma News Articles
 | Understanding Basal Cell Carcinoma: What You Need to Know by Perry Robins; MD This valuable handbook provides comprehensive, up-to-date information for patients, their families, friends, and everybody else interested in BCC. Includes four-color illustrations, FAQ, a glossary of medical terms and... |
 | Metastatic Carcinomas of Unknown Origin Metastatic Carcinomas of Unknown Origin, by Mark R. Wick, MD, is the first comprehensive, fully illustrated discussion of the clinical features, pathologic attributes, and treatment approaches of metastatic carcinomas of unknown origin (MCUOs). More than 30,000 cases of MCUOs are identified in the United States each year, and since treatment plans for tumors are predicated largely on their... |
 | The Skin Cancer Answer: The Natural Treatment for Basal and Sqamous Cell Carcinomas and Keratoses by William I. Lane, Linda Comac A complete guide to the new vegetable-based skin cancer... |
 | Hepatocellular Carcinoma This essential book is a compendium of papers written by an international team of world-renowned experts, who cover topics in their respective areas of expertise. Presenting the most up-to-date knowledge of hepatocellular carcinoma, it covers all topics -- including those more controversial ones -- in this rapidly advancing field, from epidemiology to prevention, from molecular biology to gross... |
| Surgery of Basal Cell Carcinoma of the Face by Daniel Marchac | |
| Incidental Finding: Essays on Renal Cell Carcinoma A compelling collection of personal stories, current therapies, and obstacles to overcome to create effective therapies for patients with Renal Cell... | |
 | Imaging of the Larynx (Medical Radiology / Diagnostic Imaging) This book comprehensively covers state-of-the-art cross-sectional imaging of the larynx. The radiological anatomy of the larynx is described in detail, and the imaging findings in benign and malignant laryngeal disease are extensively discussed. Post-treatment changes are carefully described. The benefit of imaging in the clinical management of laryngeal pathology is highlighted, including its... |
 | Kidney Cancer (Cancer Treatment and Research) Kidney cancer is a heterogenous disease. This book covers: -new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques; -new staging and prognostic capabilities; -evolving therapeutic options include, cell based vaccine, gene and antibody therapy; -molecular genetics allow for a better understanding of the various types of kidney... |
 | Ductal Carcinoma In Situ of the Breast Now in its Second Edition, this pioneering classic text contains the most complete discussion of DCIS available in the medical market. Includes a DCIS review and also covers biology, detection, diagnosis, pathology, psychology, and the treatment of the disease. Contributing surgeons, pathologists, radiation and medical oncologists, psychiatrists, and a medical geneticist write chapters in this... |
 | 21st Century Complete Medical Guide to Pancreatic Cancer and Islet Cell Carcinoma - Authoritative Government Documents and Clinical References for Patients ... on Diagnosis and Treatment Options by PM Medical Health News This up-to-date and comprehensive CD-ROM provides a superb collection of official Federal government documents on pancreatic cancer and islet cell carcinoma: signs and symptoms, diagnosis, lab tests, treatment and management options, and ongoing clinical research. Every aspect of the disease is thoroughly covered. There is no other reference that is as fast, convenient, and portable - everything... |
| © 2008 BrightSurf.com |